Therapeutic Areas

Swixx BioPharma’s focus is in 4 strategic therapeutic areas, launching highly innovative, new therapies in Rare disease, Oncology/Hematology, Specialty Care and Vaccines.

Swixx also commercializes multiple Consumer Healthcare products via a dedicated CHC Business Unit in a limited territory - the Baltics, West Balkans and Russia.

Rare Disease

Despite the rarity of each disease, rare diseases affect many patients worldwide.

Read more

Oncology / Hematology

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.

Read more

Specialty Care

Chronic diseases are the leading causes of death and disability worldwide.

Read more

Vaccines prevenFLU

Vaccination is one of the greatest achievements of the 20th century that reduces the burden of infectious diseases immediately after broad access to clean water.

Read more
  • BluePrint
  • Jazz Pharmaceuticals
  • Norgine
  • SeaGen
  • Otsuka
  • Bristol Myers
  • Sanofi
  • UPSA
  • GE Healthcare
  • Vifor
  • Gilead
  • Amgen
  • Alcon
  • Merz
  • Astra Zeneca
  • Kyowa Kirin
  • Fresenius
  • PTC
  • BeiGene
  • Incyte
  • BioCryst
  • Eli Lilly
  • OM Pharma
  • Pharmanutra
  • Y-mAbs


Corporate Headquarters

Swixx Biopharma AG
Neuhofstrasse 5A
CH-6340 Baar
Tel. +41 41 5523 440

Other Countries

Management Center

Hybernská 5, 11000 Praha 1
Czech Republic
Tel. +420 242 434 242

Other pages powered by SWIXX